Market analysts’ consensus outlook for this coming year seems positive, with earnings becoming less negative, reaching $-22.5M in 2019. However, earnings should fall off in the following year, reducing to $-25.9M in 2020 and $-36.0M in 2021.
While it is informative understanding the rate of growth year by year relative to today’s figure, it may be more beneficial to determine the rate at which the company is moving on average every year. The pro of this method is that it ignores near term flucuations and accounts for the overarching direction of Tonix Pharmaceuticals Holding’s earnings trajectory over time, be more volatile. To calculate this rate, I’ve appended a line of best fit through analyst consensus of forecasted earnings. The slope of this line is the rate of earnings growth, which in this case is 24.47%. This means that, we can assume Tonix Pharmaceuticals Holding will grow its earnings by 24.47% every year for the next couple of years.
For Tonix Pharmaceuticals Holding, I’ve compiled three key aspects you should further research:
1. Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
2. Management:Have insiders been ramping up their shares to take advantage of the market’s sentiment for TNXP’s future outlook? Check out our management and board analysis with insights on CEO compensation and governance factors.
3. Other High-Growth Alternatives : Are there other high-growth stocks you could be holding instead of TNXP? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!